Brian K Fox

US Patent:

6716965, Apr 6, 2004

Filed:

Nov 29, 2001

Appl. No.:

09/997610

Inventors:

Brian A. Fox - Seattle WA
James L. Holloway - Seattle WA

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K 1400

US Classification:

530350

Abstract:

The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.

US Patent:

6887695, May 3, 2005

Filed:

Mar 27, 2002

Appl. No.:

10/109084

Inventors:

Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12N009/10
C12P021/06

US Classification:

435193, 435 691

Abstract:

Transglutaminase polypeptides, polynucleotides encoding them, methods of making them, and methods of using them are disclosed. The polypeptides comprise residues 1-X of SEQ ID NO:2, wherein X is an integer from 462 to 704, inclusive. The compositions and methods of the invention may be used for a variety of purposes in industry, research, and medicine.

US Patent:

6955899, Oct 18, 2005

Filed:

Oct 17, 2003

Appl. No.:

10/688570

Inventors:

Brian A. Fox - Seattle WA, US
James L. Holloway - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K014/00
C12P021/06
C07H021/04

US Classification:

435 691, 530300, 530356, 514 12

Abstract:

The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.

US Patent:

7071299, Jul 4, 2006

Filed:

Jun 18, 2001

Appl. No.:

09/883727

Inventors:

Robert R. West - Seattle WA, US
Paul O. Sheppard - Granite Falls WA, US
Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K 7/06
C07K 7/08
C07K 14/435

US Classification:

530324, 530325, 530326, 530327, 530328, 530329, 530330

Abstract:

The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

US Patent:

7122351, Oct 17, 2006

Filed:

Oct 18, 2002

Appl. No.:

10/274638

Inventors:

Margaret Dow Moore - Seattle WA, US
Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12N 5/10
C12N 15/16
C12N 15/63

US Classification:

435 694, 4352523, 43525411, 4353201, 536 234, 536 235, 536 2351

Abstract:

Proteins consisting of two PDGF-D polypeptide chains, polynucleotides encoding the polypeptides, and materials and methods for making the proteins are disclosed. Each of the polypeptide chains consists of, from amino terminus to carboxyl terminus, the following operably linked segments: P1-P2-h-C2-C3; P1-P2-C2-C3; h-C2-C3-P2-P1; or C2-C3-P2-P1. Within these polypeptide chains, P1 is a first polypeptide segment as shown in SEQ ID NO:2 or SEQ ID NO:4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365–370, inclusive; P2 is a second polypeptide segment consisting of from 4 to 20 amino acid residues; h is an immunoglobulin hinge region or portion thereof; and C2 and C3 are C2 and C3 domains of an immunoglobulin heavy chain, respectively. Within the protein, the two polypeptide chains are joined by one or more disulfide bonds, each of the chains is optionally glycosylated, and the protein binds to and activates cell-surface PDGF receptors.

US Patent:

7122632, Oct 17, 2006

Filed:

Dec 22, 2000

Appl. No.:

09/745792

Inventors:

Donald C. Foster - Lake Forest Park WA, US
Wenfeng Xu - Seattle WA, US
Karen L. Madden - Bellevue WA, US
James D. Kelly - Mercer Island WA, US
Cindy A. Sprecher - Patagonia AZ, US
Cameron S. Brandt - Seattle WA, US
Mark W. Rixon - Issaquah WA, US
Scott R. Presnell - Tacoma WA, US
Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K 14/705
C12P 21/02

US Classification:

530351, 435 691, 435 697, 536 235

Abstract:

A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

US Patent:

7241593, Jul 10, 2007

Filed:

Feb 11, 2003

Appl. No.:

10/365095

Inventors:

Brian A. Fox - Seattle WA, US
Margaret Dow Moore - Seattle WA, US
Kristine M. Swiderek - Woodinville WA, US
Carl W. Birks - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12P 21/04
C07K 14/49

US Classification:

435 697, 530350, 530399

Abstract:

Proteins consisting of, from amino to carboxyl terminus, a first PDGF-D growth factor domain polypeptide, a linker polypeptide, and a second PDGF-D growth factor domain polypeptide, and materials and methods for making the proteins are disclosed. Each of the first and second PDGF-D growth factor domain polypeptides consists of a sequence of amino acid residues as shown in SEQ ID NO:2 or SEQ ID NO:4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365–370, inclusive. The linker polypeptide consists of from 11–40 amino acid residues. The proteins can be used to stimulate the production of bone and/or connective tissue in both humans and non-human animals.

US Patent:

7381794, Jun 3, 2008

Filed:

Mar 8, 2005

Appl. No.:

11/075351

Inventors:

Margaret D. Moore - Seattle WA, US
Brian A. Fox - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C07K 14/705
C07K 16/00

US Classification:

530350, 5303871

Abstract:

Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a second dimerizing domain.